247 related articles for article (PubMed ID: 18164930)
21. Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption.
Sarnes A; Kovalainen M; Häkkinen MR; Laaksonen T; Laru J; Kiesvaara J; Ilkka J; Oksala O; Rönkkö S; Järvinen K; Hirvonen J; Peltonen L
J Control Release; 2014 Apr; 180():109-16. PubMed ID: 24566254
[TBL] [Abstract][Full Text] [Related]
22. Molecular organization of hydrophobic molecules and co-adsorbed water in SBA-15 ordered mesoporous silica material.
Mellaerts R; Roeffaers MB; Houthoofd K; Van Speybroeck M; De Cremer G; Jammaer JA; Van den Mooter G; Augustijns P; Hofkens J; Martens JA
Phys Chem Chem Phys; 2011 Feb; 13(7):2706-13. PubMed ID: 21152589
[TBL] [Abstract][Full Text] [Related]
23. Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization.
Abd-Elrahman AA; El Nabarawi MA; Hassan DH; Taha AA
Drug Deliv; 2016 Nov; 23(9):3387-3398. PubMed ID: 27167529
[TBL] [Abstract][Full Text] [Related]
24. Multilayer encapsulated mesoporous silica nanospheres as an oral sustained drug delivery system for the poorly water-soluble drug felodipine.
Hu L; Sun H; Zhao Q; Han N; Bai L; Wang Y; Jiang T; Wang S
Mater Sci Eng C Mater Biol Appl; 2015 Feb; 47():313-24. PubMed ID: 25492202
[TBL] [Abstract][Full Text] [Related]
25. Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica.
Wang Z; Chen B; Quan G; Li F; Wu Q; Dian L; Dong Y; Li G; Wu C
Int J Nanomedicine; 2012; 7():5807-18. PubMed ID: 23209366
[TBL] [Abstract][Full Text] [Related]
26. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.
Yanyu X; Yunmei S; Zhipeng C; Qineng P
Int J Pharm; 2006 Jan; 307(1):77-82. PubMed ID: 16300915
[TBL] [Abstract][Full Text] [Related]
27. The investigation of MCM-48-type and MCM-41-type mesoporous silica as oral solid dispersion carriers for water insoluble cilostazol.
Wang Y; Sun L; Jiang T; Zhang J; Zhang C; Sun C; Deng Y; Sun J; Wang S
Drug Dev Ind Pharm; 2014 Jun; 40(6):819-28. PubMed ID: 23594300
[TBL] [Abstract][Full Text] [Related]
28. Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets.
Zhao Z; Gao Y; Wu C; Hao Y; Zhao Y; Xu J
Drug Dev Ind Pharm; 2016; 42(2):199-208. PubMed ID: 26114553
[TBL] [Abstract][Full Text] [Related]
29. Immediate release of poorly soluble drugs from starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; Remon JP; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2007 Nov; 67(3):715-24. PubMed ID: 17537625
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of ordered mesoporous silica as a carrier for poorly soluble drugs: influence of pressure on the structure and drug release.
Vialpando M; Aerts A; Persoons J; Martens J; Van Den Mooter G
J Pharm Sci; 2011 Aug; 100(8):3411-3420. PubMed ID: 21387318
[TBL] [Abstract][Full Text] [Related]
31. Mesoporous silica material TUD-1 as a drug delivery system.
Heikkilä T; Salonen J; Tuura J; Hamdy MS; Mul G; Kumar N; Salmi T; Murzin DY; Laitinen L; Kaukonen AM; Hirvonen J; Lehto VP
Int J Pharm; 2007 Feb; 331(1):133-8. PubMed ID: 17046183
[TBL] [Abstract][Full Text] [Related]
32. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs.
Wu C; Wang Z; Zhi Z; Jiang T; Zhang J; Wang S
Int J Pharm; 2011 Jan; 403(1-2):162-9. PubMed ID: 20937370
[TBL] [Abstract][Full Text] [Related]
33. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
34. Fast-dissolving microparticles fail to show improved oral bioavailability.
Wong SM; Kellaway IW; Murdan S
J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
[TBL] [Abstract][Full Text] [Related]
35. Novel chitosan-functionalized spherical nanosilica matrix as an oral sustained drug delivery system for poorly water-soluble drug carvedilol.
Sun L; Wang Y; Jiang T; Zheng X; Zhang J; Sun J; Sun C; Wang S
ACS Appl Mater Interfaces; 2013 Jan; 5(1):103-13. PubMed ID: 23237208
[TBL] [Abstract][Full Text] [Related]
36. Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen, and ibuprofen.
Vialpando M; Backhuijs F; Martens JA; Van den Mooter G
Eur J Pharm Biopharm; 2012 May; 81(1):190-8. PubMed ID: 22306694
[TBL] [Abstract][Full Text] [Related]
37. In situ FT-IR investigation of etravirine speciation in pores of SBA-15 ordered mesoporous silica material upon contact with water.
Mellaerts R; Fayad EJ; Van den Mooter G; Augustijns P; Rivallan M; Thibault-Starzyk F; Martens JA
Mol Pharm; 2013 Feb; 10(2):567-73. PubMed ID: 23252337
[TBL] [Abstract][Full Text] [Related]
38. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.
Simovic S; Heard P; Hui H; Song Y; Peddie F; Davey AK; Lewis A; Rades T; Prestidge CA
Mol Pharm; 2009; 6(3):861-72. PubMed ID: 19358600
[TBL] [Abstract][Full Text] [Related]
39. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan.
Zhang Y; Zhi Z; Jiang T; Zhang J; Wang Z; Wang S
J Control Release; 2010 Aug; 145(3):257-63. PubMed ID: 20450945
[TBL] [Abstract][Full Text] [Related]
40. Cryogenic liquids, nanoparticles, and microencapsulation.
Purvis T; Vaughn JM; Rogers TL; Chen X; Overhoff KA; Sinswat P; Hu J; McConville JT; Johnston KP; Williams RO
Int J Pharm; 2006 Oct; 324(1):43-50. PubMed ID: 16814968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
